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Abstract 
Rhinitis and rhinosinusitis are the two major clinical entities of chronic upper airway disease. Chronic rhinosinusitis 
(CRS) and allergic rhinitis (AR) affect respectively up to 10 and 30% of the total population, hence being associated 
with an important socio-economic burden. Different phenotypes of rhinitis and CRS have been described based on 
symptom severity and duration, atopy status, level of control, comorbidities and presence or absence of nasal polyps 
in CRS. The underlying pathophysiological mechanisms are diverse, with different, and sometimes overlapping, endo-
types being recognized. Type 2 inflammation is well characterized in both AR and CRS with nasal polyps (CRSwNP), 
whereas type 1 inflammation is found in infectious rhinitis and CRS without nasal polyps (CRSsNP). The neurogenic 
endotype has been demonstrated in some forms of non-allergic rhinitis. Epithelial barrier dysfunction is shown in AR 
and CRSwNP. Emerging therapies are targeting one specific pathophysiological pathway or endotype. This endotype-
driven treatment approach requires careful selection of the patient population who might benefit from a specific 
treatment. Personalized medicine is addressing the issue of providing targeted treatment for the right patient and 
should be seen as one aspect of the promising trend towards precision medicine. This review provides a comprehen-
sive overview of the current state of endotypes, biomarkers and targeted treatments in chronic inflammatory condi-
tions of the nose and paranasal sinuses.
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Background
Persistent rhinitis and chronic rhinosinusitis (CRS) are 
the two major clinical entities of chronic upper airway 
disease. Worldwide questionnaire-based surveys show 
that allergic rhinitis affects up to 30% of the global popu-
lation, whereas CRS is present in over 10% of the Euro-
pean population [1, 2]. Upper airway diseases are often 
associated with comorbidities such as asthma or COPD 
[3, 4]. The upper and lower airways cannot be separated 
from each other and immune modulating drugs, such as 
allergen immunotherapy and biologicals, affect both air-
way compartments.
Uncontrolled disease has been reported in 35–40% 
of patients with chronic upper airway disease and has a 
substantial impact on the patient’s social, physical and 
economic health. The reasons for an uncontrolled disease 
are related to disorder-, diagnosis-, treatment- or patient-
associated factors. The relative importance of these fac-
tors is unclear, specialists agree that optimal disease 
management approaches are needed [5–7].
Precision medicine is proposed to address this global 
issue by providing customized and individualized care 
based on the unique immunologic, genetic and psycho-
social profile of the patient [8]. The concept of precision 
medicine is based on four pillars: personalized care with 
tailored diagnostic and therapeutic approaches, predic-
tion of disease progression and success of treatment, 
prevention of disease and participation of the patient to 
achieve good adherence and optimal efficacy of the given 
treatment.
To fully implement precision medicine into daily prac-
tice, disease management based on disease control and 
phenotyping needs to be complemented with disease 
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endotyping. For decades, to determine the best-fit treat-
ment, a phenotype is being assigned to the patient based 
on clinical symptoms, atopy status and the presence of 
nasal polyps (for CRS patients). This approach is gener-
ally carried out almost entirely regardless of the underly-
ing pathophysiological mechanisms. In complex diseases 
with mixed pathophysiologies, a phenotype-driven treat-
ment is not always sufficient to obtain optimal control. 
Endotype classification based on thorough investiga-
tion of the underlying pathophysiological mechanisms is 
therefore gaining more interest. Endotyping will provide 
more insight in the inter-individual variability of clini-
cal presentation and treatment response in patients with 
identical phenotypes. In addition, endotyping might in 
the future guide the decision making process of targeted 
treatments [9]. In order to make endotype-driven treat-
ment a clinical applicable approach in daily practice, 
identification of measurable biological indicators, or so 
called “biomarkers”, is needed [10]. The ideal biomarker 
serves as a signature of a well-defined endotype and is 
easily measurable, reproducible and affordable [11].
Currently we are in the era of extensive research 
towards identification of biomarkers and endotype-
driven treatments. Research on endotyping is also per-
formed for asthma and cancer and is well ahead of 
endotyping in upper airway diseases. The aim of the cur-
rent review is to provide a comprehensive overview of 
the current state of endotypes, biomarkers and biological 
treatment in rhinitis and CRS. Since biomarkers can be 
used for many applications, only those that are (poten-
tially) of valuable for the diagnosis or prediction of treat-
ment response will be reviewed. Subsequently, current 
or potential treatment strategies targeting specific endo-
types will be discussed.
Endotypes and biomarkers in upper airway 
diseases
Rhinitis is characterized by inflammation of the nasal 
mucosa causing nasal obstruction, rhinorrhoea, sneez-
ing and pruritus [12]. Three main phenotypes of rhinitis 
are described: allergic rhinitis (AR), infectious rhinitis 
and non-allergic non-infectious rhinitis (NAR). The lat-
ter phenotype can be subdivided in many subpheno-
types such as idiopathic rhinitis (IR), hormonal rhinitis, 
gustatory rhinitis, drug-induced rhinitis, rhinitis of the 
elderly, atrophic rhinitis and occupational rhinitis [13]. 
In CRS the mucosal inflammation affects the nose and 
paranasal sinuses and is characterized by nasal obstruc-
tion and discharge, loss of smell and/or facial pain, which 
lasts longer than 12  weeks [14]. Traditionally a pheno-
type is addressed to the patient according to the presence 
(CRSwNP) or absence (CRSsNP) of nasal polyps on nasal 
endoscopy or radiological imaging.
A specific phenotype can be indicative for the pres-
ence of one particular endotype. However, one or mixed 
endotype(s) can also underlie different phenotypes in 
upper airway diseases, hence making clear distinction of 
endotypes more complex. Since the underlying patho-
physiological events of both rhinitis and CRS are located 
at the upper airway mucosal lining, they share common 
endotypes (Fig. 1).
Type 2 inflammation
Type 2 inflammation is characterized by the presence 
of eosinophils and type 2 cytokines IL-4, IL-5, IL-9 and 
IL-13, derived from Th2 cells and type 2 innate lymphoid 
cells (ILC2), in peripheral blood or nasal mucosa [15]. 
IL-25, IL-31, IL-33 and thymic stromal lymphopoietin 
(TSLP) secreted by epithelial cells are known to induce 
or enhance type 2 driven inflammation [16]. In sensitized 
individuals, contact with allergens activates mast cells 
via immunoglobulin E (IgE) dependent mechanisms [9] 
(Fig. 2).
Type 2 inflammation is a major feature of AR, local 
allergic rhinitis (LAR) and CRSwNP, hence the most 
common and studied endotype in upper airway diseases 
(Table 1). Topical and/or oral corticosteroids are the first-
line treatment for these patients and are shown to reduce 
eosinophils in nasal mucosa [17–19]. However, treatment 
with corticosteroid can be insufficient to fully control the 
inflammation.
AR is predominantly defined by the type 2 endotype. 
Allergen exposure through nasal mucosa triggers the 
type 2 inflammatory cascade leading to a Th2-dominant 
milieu with eosinophilia and specific IgE production 
[20]. The diagnosis of AR is based on clinical features and 
allergen sensitization. A positive skin prick test (SPT) or 
ImmunoCap test, using rather arbitrary cut-off values 
of wheal diameter ≥3  mm and serum IgE ≥  0.35 KU/l, 
are used to confirm atopic sensitization [21]. A negative 
SPT however, does not exclude presence of type 2 inflam-
mation, e.g. LAR. Additional nasal allergen provocation 
test and nasal secretion sampling for specific IgE detec-
tion can provide evidence of type 2 inflammation [22]. In 
addition, serum total IgE, eosinophilic cationic protein 
(ECP, activation marker of eosinophils) and eosinophils 
have been proposed as diagnostic biomarkers with cor-
responding cut-off values of 98.7 IU/mL, 24.7 µg/mL and 
4.0%, respectively, with sensitivities ranging from 55.7 to 
75.2% and specificities from 69.7 to 74.4% [23]. Type 2 
cytokines IL-4, IL-5 and IL-13 are also detectable in nasal 
fluids [24]. So far, no validated diagnostic cut-off values 
are available.
Unlike AR, type 2 inflammation in CRSwNP is char-
acterised by polyclonal IgE formation and is usually not 
linked to atopy [25]. This endotype is the most common 
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Fig. 1 Overview of endotypes and phenotypes in rhinitis and chronic rhinosinusitis. Endotype predominantly underlying the phenotype, solid lines; 
endotype potentially contributing to the phenotype, dashed lines. AR allergic rhinitis; CRSsNP chronic rhinosinusitis without nasal polyps; CRSwNP 
chronic rhinosinusitis with nasal polyps; IR idiopathic rhinitis; RoElderly rhinitis of the elderly; Gustatory R gustatory rhinitis
Fig. 2 Type 2 inflammation and biologicals. B B cell; baso basophil; DC dendritic cell; ECP eosinophilic cationic protein; eos eosinophils; ILC2 type 2 
innate lymphoid cell; Th T helper cell
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one in white people from Europe and US with eosino-
philic CRSwNP [26–28].
In research setting, the diagnosis of eosinophilic 
CRSwNP is either based directly on tissue eosinophilia 
(>5 eosinophils/high power field or indirectly on ECP/
myeloperoxidase (MPO) ratio (>1) determined on nasal 
biopsies [26, 27, 29]. A cut-off value of >10 eosinophil/
HPF however is clinically more relevant to assess its 
impact on quality of life (QoL) [30]. One cross-sectional 
study with 51 patients shows that serum eosinophilia val-
ues of >0.3 ×  109  L−1 or 4.4% of white blood cells have 
a positive predictive value and negative predictive value 
of 79 and 67%, respectively [31]. Furthermore, type 2 
cytokines IL-4, IL-5 and IL-13 are detectable in nasal 
secretions. Surprisingly IL-13 levels were elevated in 
samples of healthy controls compared to those of patients 
with CRSsNP and CRSwNP, and IL-4 levels showed no 
significant raise. IL-5 was significantly higher in presence 
of nasal polyps compared to CRSsNP and healthy con-
trols and might therefore be a useful biomarker to predict 
ongoing type 2 inflammation in CRSsNP patients [32]. 
Hence, all the above-mentioned markers, corresponding 
cut-off values and predictive values need to be validated 
in larger cohorts of patients.
Some studies evaluated the potential of type 2 inflam-
matory markers as prognostic biomarkers. Higher levels 
of mucosal and/or blood eosinophilia and presence of 
comorbid asthma are correlated with poor outcome in 
terms of QoL, recurrence of NP after sinus surgery and 
disease severity [29, 30, 33–35]. Other type 2 inflamma-
tion markers such as IgE, ECP and IL-5 are also predic-
tive for recurrence of CRSwNP [28, 36].
Staphylococcus aureus is found in around 60% of CRS 
patients with eosinophilic inflammation and NP [37]. 
Whether S. aureus is an initiator or amplifier in CRS is 
a matter of debate. S. aureus biofilms are documented in 
CRS patients with more severe disease and worse post-
operative outcome [38, 39]. Biofilms make bacteria more 
resistant to therapy with antibiotics, thus allowing them 
to penetrate submucosally and initiate type 2 inflamma-
tion. IL-4 and IL-13 may also compromise the immune 
response to S. aureus through the suppression of human 
β-defensin released in skin and mucosa [40, 41]. Impor-
tantly, S. aureus produces enterotoxins (SE) which can act 
as superantigens. These superantigens have the unique 
ability to amplify the type 2 inflammation through inter-
action with T-cells via the T cell receptors, as a result of 
their unrestricted antigen specificity, and in turn lead-
ing to the production of polyclonal IgE against SE (SE-
IgE) [42]. Presence of SE-IgE itself is a risk factor for the 
development of comorbid asthma [26, 36, 37, 43, 44], and 
NP recurrence after surgery [28].
Table 1 Potential diagnostic biomarkers
ECP eosinophilic cationic protein; MPO myeloperoxidase; TER transepithelial resistance; TJ tight junctions; TRPV1 transient receptor potential cation channel subfamily 
V receptor 1
* Also detectable in nasal biopsies
Endotypes Allergic rhinitis Idiopathic rhinitis Infectious rhinitis CRSwNP CRSsNP
Type 2 inflammation
Serum Eosinophils*
Total IgE
Specific IgE
ECP*
Eosinophils*
Total IgE*
IgE/SE-IgE*
ECP*
Nasal fluids Total/specific IgE*
IL-5*
IL-4, IL-13*
Eosinophils*
Total/specific IgE*
IL-5*
IL4, IL-13
ECP/MPO ratio*
ECP*
Non-type 2 inflammation
Nasal lavage/fluids IL-1P, IL-6, IL-8, MPO
IFNγ
TNFα
IL-1P, IL-6, IL-8, MPO*
IFNγ*
IL-17, IL-22, TNFα*
Nasal biopsy Neutrophils Neutrophils
Neurogenic endotype
Nasal fluids SP
Nasal biopsy TRPV1
Barrier dysfunction
Nasal biopsy ↓TER ↓TER ↓TER
↓TJ ↓TJ ↓TJ ↓TJ
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Non‑type 2 inflammation
Non-type 2 inflammation is mainly characterized by 
neutrophils in nasal mucosa [27, 44, 45]. Neutrophilic 
inflammation can be triggered by infections or chronic 
irritation, such as air pollution. This leads to dysregula-
tion of the innate immune system and activation of the 
IL-17 pathway with recruitment of neutrophils to the 
nasal mucosa, which is known to be mediated via IL-8 
[46–48]. In addition, type 1 immune response, metabolic 
and epigenetic factors, or the activation of the epithelial-
mesenchymal trophic unit may lead to extensive remod-
eling without any inflammation, have been identified as 
modulating factors of the neutrophilic inflammation [49, 
50] (Fig. 3).
Research on endotyping in non-type 2 inflamma-
tory diseases lags well behind the type 2 inflammatory 
diseases, and so far no endotype-driven treatment has 
been proven to be effective. Since tissue neutrophilia is 
associated with reduced clinical response to corticoster-
oids, further exploration of none-type 2 is needed [18, 
51].
Infectious rhinitis is associated with neutrophilic 
inflammation with increased pro-inflammatory cytokines 
IL-1β, IL-6, IL-8, interferon (IFN) γ, tumor necrosis 
factor (TNF)α and MPO [52, 53]. These cytokines can be 
detected in nasal lavage samples during acute upper res-
piratory tract infection.
CRSsNP is generally associated with neutrophilic 
inflammation and increased levels of IFNγ and IL-17, 
although it has also been documented in CRSwNP, espe-
cially in the Asian population [26]. Based on the study 
of Tomassen et  al. three non-type 2 subendotypes were 
identified in patients with CRS: (1) neutrophilic inflam-
mation characterized by pro-inflammatory cytokines 
IL-1β, IL-6, IL-8 and MPO; (2) Th17- or Th22- driven 
inflammation characterized by IL-17, IL-22 and TNFα; 
(3) Th1-driven inflammation characterized by IFNγ [44]. 
A combination of these subendotypes are often docu-
mented in both CRSsNP and CRSwNP, hence resulting 
in a mixed endotype [26]. During early stage CRSsNP, 
increased levels of transforming growth factor (TGF) β1 
in sinus tissue compared to turbinate tissue from controls 
were reported, suggesting that TGFβ1 plays a pivotal role 
in initiating collagen production and remodelling process 
[54]. In CRSwNP patients with non-recurrent disease, 
higher levels of IFNγ indicative of Th1-driven inflamma-
tion were found compared to those with recurrent dis-
ease [28].
Fig. 3 Non-type 2 inflammation and biological. None-type 2 hosts different T helper subsets. Th1 cells, Th17 and Th22 cells characterized by their 
individual transcription factors (T-bet, RORyt, AHR) are responsible for Th1, Th17 and Th22 cytokines respectively. Regulatory T cells suppress the 
immune response via production of IL-10 and TGF-β. DC dendritic cell; neu neutrophils; Th T helper cell; Treg T regulatory cell
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Neurogenic activation
Dysfunction of the neuronal system of the nose is under-
lying different subphenotypes of NAR such as idiopathic 
rhinitis (IR), gustatory rhinitis and rhinitis of the elderly 
[55]. Two pathophysiological mechanisms are proposed: 
1/overexpression of transient receptor potential (TRP) 
channels and associated nasal hyperreactivity (NHR) and 
2/imbalance of sympathetic and parasympathetic system 
[56] (Fig. 4).
NHR is present in two-thirds of patients with IR, i.e. 
aberrant reactivity of the nasal mucosa to common envi-
ronmental stimuli such as smoke, chemical pollutants, 
strong odors and temperature and humidity alterations 
resulting in defensive responses such as sneezing, rhi-
norrhoea and nasal congestion [57]. The nasal mucosa is 
equipped with C-fibers, a specific type of sensory nerve, 
which express TRP channels on their endings. These 
nerves can be activated by non-allergic triggers, such 
as environmental irritants, alterations in temperature 
or osmolality, and can subsequently induce the release 
of neuropeptides like substance P (SP) and calcitonin 
G-related peptide (CGRP). These neuropeptides induce 
increased vascular permeability and glandular hyperse-
cretion resulting in the above-mentioned rhinitis symp-
toms [56].
Van Gerven et al. demonstrated an association between 
IR and TRP subfamily V receptor 1 (TRPV1) overexpres-
sion in nasal mucosa. In addition, increased SP levels 
were found in nasal secretions of IR patients, support-
ing a causative role of the nociceptive TRPV1-SP sign-
aling pathway [57]. Evaluation of SP in nasal secretions 
could potentially serve as a diagnostic biomarker for IR. 
However, more easy and rapid tests are required to allow 
identification of IR patients in daily practice. The cold-
dry air provocation test (CDA) is a diagnostic test for 
NHR with a high sensitivity and specificity, thus provid-
ing a reliable, easy, well-tolerated but most importantly 
non-invasive test using natural stimuli compared to a 
more labor intensive nasal sampling [58].
Moreover, the imbalance of the autonomous nervous 
system, also called “dysautonomia” might also contribute 
to the pathophysiological mechanism of NAR. Parasym-
pathetic and sympathetic activity results in vasodilation 
and vasoconstriction, respectively. An imbalance of these 
components with loss of sympathetic tone and relative 
increased parasympathetic activity, results in vasodila-
tion, increased mucosal blood flow and glandular hyper-
secretion [56]. Although the pathophysiology of rhinitis 
of the elderly is not clear, dysautonomia is thought to be 
the causative mechanisms leading to the typical clear rhi-
norrhea [13]. So far no biomarkers are evaluated to iden-
tify patients with dysautonomia.
Epithelial barrier dysfunction
The epithelial lining forms the first barrier for exogenous 
pathogens or harmful particles. Besides being a physical 
barrier and maintaining mucociliary clearance, it modu-
lates the innate immune response by through cytokine 
and chemokine production [59]. Proper functioning of 
the physical barrier is supported by dynamic junctional 
complexes that connect epithelial cells to one another 
and regulate paracellular flux of molecules of a certain 
size. Tight junctions are apically located epithelial junc-
tions, consisting of different transmembrane proteins 
Fig. 4 Neurogenic endotype and biologicals. TRPV1 overexpression resulting in nasal hyperreactivity on temperature and/or osmolality changes 
and irritants (left side). Dysautonomia (right side). CGRP calcitonin G-related peptide; SP substance P; TRPV1 transient receptor potential vanniloid 1
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such as claudin-1, claudin-4, occludin and junctional 
adhesion molecule A, which are connected to intracellu-
lar proteins like zonula occludens-1 (ZO-1) among others 
(Fig. 5).
A defective epithelial barrier has been documented in 
various chronic airway diseases, such as AR, CRS and 
asthma, and is associated with chronicity and sever-
ity of the inflammation [60–62]. A leaky epithelium was 
documented in CRSwNP due to decreased expression of 
occludin and claudin-4 on nasal biopsies [61]. Similarly 
a disrupted tight junction arrangement in AR was found 
to be due to decreased expression of occludin and ZO-1 
[62].
Whether epithelial barrier dysfunction is a primary 
genetic event or a secondary phenomenon resulting 
from inflammation is not clear. A dysfunctional epithe-
lial barrier results in increased permeability for foreign 
particles allowing them to migrate to the submucosal 
region, hence making it more vulnerable for inflamma-
tion. In addition, there is evidence that IL-4 disrupts 
epithelial integrity suggesting that type 2 inflammation 
can contribute to epithelial dysfunction [62]. Since epi-
thelial barrier dysfunction is part of AR and CRS, restor-
ing the barrier integrity may become a useful treatment 
approach. So far, no easy methods are available to 
evaluate barrier function in patients with upper airway 
disease.
Treatment of chronic upper airway disease
Therapies targeting type 2 inflammation
Targeting IgE‑pathway
Omalizumab, a recombinant humanized anti-IgE mon-
oclonal antibody (mAb), binds circulating IgE on its 
high-affinity receptor (FcεRI) preventing it to become 
cell-bound on effector cells such as mast cells, basophils, 
dendritic cells and eosinophils. Subsequently the expres-
sion of FcεRI reduces on the effector cells [63–65]. Omal-
izumab is approved by the European and US regulatory 
authorities for the treatment of severe allergic asthma 
and is currently under investigation for its use in the 
treatment of allergic rhinitis and CRS (Table 2).
Cumulative evidence exists that treatment with omali-
zumab is safe, well-tolerated and effective in reducing 
symptoms and rescue medication use in AR [66–73]. 
Adding omalizumab to allergen immunotherapy (AIT) 
for the treatment of allergic rhinitis with or without co-
morbid allergic asthma appears to be superior to either 
treatments alone [72, 74, 75]. Combination therapy 
shows superiority in the treatment of polysensitized 
patients, due to its allergen-independent therapeutic 
Fig. 5 Barrier dysfunction and potential biomarkers. EGF epidermal growth factor; EGF-R epidermal growth factor receptor; JAM-A junctional adhe-
sion molecule A; TLR toll-like receptor; ZO zona occludens
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effect [76]. Furthermore, it has a protective effect on 
the development of adverse events of AIT, hence allow-
ing rush-immunotherapy treatment with higher dose 
regimens and a shorter treatment course [72, 76, 77]. In 
patients with persistent AR and concomitant asthma, 
omalizumab is effective in preventing asthma exacerba-
tion and improving quality of life [78, 79]. Unfortunately, 
omalizumab has no long-term effect [80, 81] unlike AIT, 
which remains the sole curative approach nowadays.
In CRSwNP patients and co-morbid asthma omali-
zumab showed reduced upper and lower airway symp-
toms, endoscopic nasal polyp score as well as less needs 
for further medical or surgical treatments [25, 82, 83]. On 
the other hand, one trial revealed that the molecule had 
a small and clinically irrelevant effect on CRS [84]. This 
trial however was underpowered and the presence of NPs 
was not taken into account. This emphasizes the impor-
tance of endotyping to properly select patients who will 
benefit most from anti-IgE treatment.
New promising biologicals targeting IgE are being 
developed with the aim of improving anti-IgE treatment. 
One such is ligelizumab, an anti-IgE mAb with greater 
affinity for IgE compared to omalizumab [85]. A sec-
ond one is quilizumab, a mAb targeting the M1 epitope 
on membrane IgE [86]. Studies are currently running to 
assess their safety and efficacy in the treatment of asthma.
Targeting IL5‑pathway
IL-5 is a key mediator in type 2 eosinophilic inflamma-
tion [26, 28, 36, 87]. It is responsible for survival, matu-
ration and activation of eosinophils at the bone marrow 
and the site of inflammation [87–89]. To interfere with 
the IL-5 pathway, novel biologicals are developed tar-
geting IL-5 or its receptor IL-5Rα on the effector cells. 
Mepolizumab and reslizumab are both humanized anti-
IL5 mAb that neutralize IL-5. Both biologicals are already 
approved by the European and US Food and Drug Asso-
ciation (FDA) for its use in the treatment of severe eosin-
ophilic asthma.
A phase II trial showed that reslizumab, at a dose of 
one single intravenous injection of 3 mg/kg, significantly 
reduces blood eosinophil counts and nasal IL-5 levels in 
patients with NP [88]. Individual NPs score improved for 
up to 4 weeks in only 50% of the patients. Additional post 
hoc analysis could identify a subpopulation of responders 
characterized by increased IL-5 levels in nasal secretions 
(i.e. >40 pg/mL).
A phase II trial with mepolizumab showed, similar to 
reslizumab, a reduction of blood eosinophil count par-
alleled by decreased levels of IL-5 in serum and nasal 
secretions of patients with CRSwNP [89]. However, nasal 
IL-5 and nasal total IgE were not significantly altered. 
More important, a reduction of the NP score was seen 
in patients with severe and/or recurrent NP after treat-
ment with two single intravenous injections of 750  mg 
of Mepolizumab with an interval of 4 weeks. This study 
could however not support the association between 
responders and increased IL-5 levels, which presumably 
is due to a small sample size. A sustained effect for up to 
36 weeks after treatment with mepolizumab was seen in 
the responder group, suggesting its long-term effect.
Reslizumab and Mepolizumab are both safe and well-
tolerated in patients with CRSwNP. After treatment 
cessation rebound eosinophilia was reported, but this 
phenomenon seemed to occur without major exacerba-
tion symptoms [88]. Studies with larger sample size, long 
treatment duration and follow-up are needed to deter-
mine the optimal treatment scheme for clinical use [89].
Lastly, it is worth noting that benralizumab is a human-
ized mAb against the highly expressed IL-5Rα receptor 
on eosinophils [90]. Its efficacy and safety in uncontrolled 
asthma with eosinophilia has been demonstrated in a 
phase III trial. So far, no studies are published on its use 
in upper airway diseases.
Targeting IL‑4/IL‑13 ‑pathway
IL-4 and IL-13 can be seen as sibling cytokines as they 
share the IL-4Rα subunit to form a fully functional IL-4 
(with common γC subunit) or IL-4 and IL-13 (with 
IL-13Rα subunit) receptor [91]. This explains their 
mutual and important role in the type 2 inflammation.
Dupilumab, a fully human anti-IL4Rα mAb, is designed 
to interfere with this pathway. It has been proven to 
be effective in the treatment of atopic dermatitis and 
asthma, in which it also improved sinonasal symptoms 
[92, 93]. Recently a phase II trial evaluating dupilumab 
in the treatment of uncontrolled CRSwNP was published 
by Bachert et al. [94]. Adding dupilumab subcutaneously 
once every week to intranasal corticosteroid treatment 
showed improved endoscopic NP score, CT score (Lund–
Mackay scoring system), QoL and major symptoms such 
as loss of smell, nasal obstruction or congestion and noc-
turnal awakenings. This effect remained up to 16 weeks 
after treatment cessation. Further studies are needed to 
assess longer treatment duration and direct comparison 
with other type 2 biological treatments.
Other type 2 directed therapies
Chemoattractant receptor homologous molecule on Th2 
cells CRTH2 is responsible for eosinophil, basophil and 
lymphocyte recruitment upon PGD2 release of activated 
mast cells. The CRTH2-antagonist, OC000459, showed 
improvement of nasal and ocular symptoms in grass pol-
len allergic patients after grass pollen provocation [95]. 
Another CRTH2 antagonist, BI 671800, reduced total 
nasal symptoms in patients with seasonal allergic rhinitis 
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after grass pollen provocation [96]. A comparative study 
including 146 patients found that its efficacy on nasal 
symptoms score was superior to montelukast, but infe-
rior to intranasal fluticasone furoate [96].
GATA-3 is an important transcription factor and con-
sidered to be a ‘master switch’ of type 2 inflammation. It 
is responsible for the differentiation of Th0 cells towards 
Th2 cells and promotes the production of IL-4, IL-5 and 
IL-9 [97]. Significantly higher levels of GATA-3 mRNA 
has been documented in eosinophilic NP [98]. The use of 
a GATA-3 specific DNAzyme in the treatment of allergic 
asthma has been investigated in a phase IIb study, which 
reported a significant attenuation of asthmatic responses 
after allergen provocation, together with an attenuation 
of Th2-regulated inflammation [99]. So far, these targeted 
treatments have not been investigated in rhinitis or in 
CRS.
Siglec-8 is a cell surface receptor selectively expressed 
on mast cells, eosinophils and basophils [100]. Cur-
rently, a phase II study is ongoing to evaluate the efficacy 
of AK001, a monoclonal antibody targeting siglec-8, in 
patients with CRSwNP.
Allergen immunotherapy (AIT)
AIT is the only potential curative treatment option 
for IgE-mediated allergic diseases. The mechanisms of 
action of AIT include very early desensitization of mast 
cells and basophils, early generation of allergen-specific 
regulatory T cells (Treg) and B cells (Breg), suppression 
of Th2 and Th1 cells and late decrease of IgE/IgG4 ratio, 
tissue mast cell count and eosinophil counts [101]. This 
results in a reduced type 1 hypersensitivity reaction upon 
specific allergen exposure.
Currently there are two types of AIT applied in clinical 
practice, i.e. subcutaneous and sublingual immunother-
apy AIT (respectively SCIT and SLIT). Despite the fact 
that both types of AIT have proven efficacy for different 
types of allergens, it is difficult to predict response to this 
treatment. Nonetheless, different biomarkers have been 
evaluated to identify AIT-responsive endotypes.
Several studies have shown that increased IgG4 lev-
els in serum are associated with clinical improvement 
[102, 103]. Determination of allergen-specific IgE and 
IgG4 antibody levels via microarrays has been proposed 
as a potential biomarker to monitor AIT. Wollman et al. 
Table 2 Targets and potential treatments according to the specific endotypes and phenotypes
IN intranasal; IV intravenous; po per os; sc subcutaneous
Endotypes‑targets Allergic rhinitis Idiopathic rhinitis Infectious rhinitis CRSwNP CRSsNP
Type 2 inflammation
IgE Omalizumab (sc/iv) Omalizumab 
(sc)
Legelizumab Legelizumab
Ml prime mIgE Quilizumab Quilizumab
IL-5 Mepolizumab Mepolizumab 
(iv)
Reslizumab Reslizumab (sc)
IL-5Ra Benralizumab Benralizumab
IL-4/13 Dupilumab Dupilumab (sc)
CRTH2 OC000459 (po) OC000459
BI 671800 (po) BI671800
GATA-3 GATA-3 spec.DNAzyme GATA-3 spec.
DNAzyme
Siglec-8 AK001
Non-type 2 inflammation
Neutrophilic inflammation
Th1
Th17/Th22 Brodalumab Brodalu-
mab
Neurogenic endotype
TRPV1 Capsaicin (in)
SB-705498 (IN)
Barrier dysfunction
None
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demonstrated that an IgG4 induced reduction of aller-
gen-specific IgE binding has a high predictive value of 
90% for clinical improvement. This assumption is based 
on the correlation between decreased allergen-specific 
IgE binding on Immuno Solid-phase Allergen Chip 
(ISAC) microarray and increased nasal tolerance in prov-
ocation tests [104]. Another clinical study performed by 
Schmid et al. showed that pre-treatment-specific IgE lev-
els on ISAC microarray could predict the induction and 
magnitude of the IgG4 response during SCIT. Moreover, 
elevated IgE levels before treatment is thought to be a 
prerequisite for induction of IgG4 blocking antibodies. 
In addition IgE and IgG4 levels correlate with other func-
tional immunological changes such as facilitated antigen 
binding, basophil sensitivity and clinical symptoms score 
[105].
Therefore, measuring IgE levels on serum samples 
before and after updosing could be used as a biomarker 
for early monitoring of AIT. This could be particularly 
useful in patients with uncertain clinical improvement 
upon AIT. For example, when IgE levels are decreased, 
AIT can be pursued aiming at further reduction of IgE. 
On the other hand, when no change or increase of the IgE 
levels or absence of IgG4 blocking antibodies is observed 
AIT should be modified or discontinued.
Another biomarker was proposed by Shamji et al. who 
demonstrated that ex  vivo basophil hyporesponsiveness 
to allergen, confirmed with flow cytometry for intracellu-
larly labelled diamine oxidase on blood samples, is useful 
to monitor efficacy and induction of allergen-specific tol-
erance during AIT [106]. Suppression of basophil respon-
siveness and subsequent histamine release was correlated 
with lower AR symptoms scores.
Several attempts are made to establish biomarkers for 
monitoring AIT. It appears essential that the proposed 
biomarkers should be compared with each other in 
regards to their predictive value as well as their repro-
ducibility, complexity of measurement and cost-effective-
ness. Further research towards biomarkers are needed 
and will generate essential information to create novel 
and improved AIT models.
Therapies targeting non‑type 2 inflammation
Development of novel therapies targeting non-type 2 
inflammation seems more challenging compared with 
type 2 inflammation. Different biologicals have been 
investigated but these showed only little or no improve-
ment in clinically relevant asthma outcome parameters.
CXC chemokine 2 receptor (CXCR2) antagonists (e.g. 
AZD5069, SCH527123) target the CXCR2 receptors on 
neutrophils and prevent their activation through the 
chemokine IL-8. Their efficacy has been investigated 
in the treatment of severe asthma, in which no clinical 
improvement was seen, despite reduction of neutrophils 
in sputum and blood [107, 108].
Brodalumab is a human anti-IL17A mAb designed to 
target IL-17A, a cytokine that is associated with neutro-
philic inflammation and corticosteroid resistance. A trial 
of brodalumab in patients with uncontrolled moderate to 
severe asthma, without being selected for neutrophilic 
inflammation, reported no improvement of symptoms or 
lung function [109].
So far, no trials evaluating targeted treatments of non-
type 2 inflammation have been conducted in rhinitis or 
CRS. The relative poor evolution in the development of 
biologicals targeting non-type 2 inflammation indicates 
that the non-type 2 inflammation needs further research 
to identify distinct subendotypes.
Therapies targeting neurogenic activation
Targeting TRPV1 pathway
Capsaicin, the pungent substance in red pepper respon-
sible for a burning sensation, has been proven to be 
effective in reducing NHR symptoms in IR [57, 110]. 
Capsaicin activates the TRPV1 channel which leads to 
influx of  Ca2+ resulting in neuronal excitation and release 
of neuropeptides, followed by a long-lasting refractory 
period, during which the neurons are not responsive any-
more to a broad range of stimuli. Its therapeutic effect is 
thought to be due to the above-mentioned de-functional-
ization and/or degeneration of C-fibers by massive  Ca2+ 
influx [57]. Significant and long-term reduction (up to 
9  months after treatment cessation) of NHR symptoms 
have been reported [111].
To optimize the treatment with capsaicin a study was 
performed comparing two regimens: application of five 
doses of capsaicin on one single day versus one dose 
of capsaicin every 2  days for 2  weeks. Both regimens 
seemed to be equally effective, but the former scheme is 
preferred as it is thought to enhance patient compliance 
[110].
An alternative therapeutic option is targeting the 
TRPV1 ion-channel with the selective TRPV1 antagonist 
SB-705498. Reduction of NHR symptoms due to intrana-
sal application of SB-705498 has been documented [112] 
So far, no head-to-head trial has been performed com-
paring capsaicin and SB-705498.
Therapies targeting epithelial barrier dysfunction
Restoring epithelial barrier function might reduce 
excessive penetration of allergens and/or harmful par-
ticles into the submucosal space, ultimately impeding 
continuous activation of the immune system and sub-
sequent symptoms. Interfering with Toll like receptor 
or epidermal growth factor receptor signaling has been 
demonstrated to have barrier modulating capacity in 
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different in vitro and murine studies (reviewed in Stee-
lant et  al.) [113]. Whether these treatments might also 
lead to clinical improvement of symptoms needs to be 
investigated.
Recent findings suggest that the therapeutic effect of 
locally applied corticosteroids might also result from 
their ability to enhance barrier integrity [62]. Since dec-
ades, corticosteroids are part of the standard treatment 
of the upper and lower airway diseases because of their 
anti-inflammatory properties [114, 115]. It was recently 
demonstrated that corticosteroids upregulate tight junc-
tion expression and thereby restore barrier function both 
in primary epithelial cell cultures and in a model of house 
dust mite (HDM)-induced allergic airway inflammation 
[62]. In addition, HDM AR patients taking inhaled ster-
oids showed reduced epithelial permeability compared to 
steroid-naive patients [62].
Current challenges in endotype‑driven treatments
The recently gained insight into different pathophysiologi-
cal mechanisms of rhinitis and CRS has been the driving 
force for the development of targeted therapies for patients 
with chronic upper airway disease. This evolution instigates 
the development of strategies to identify those patients 
who are most likely to benefit from these therapies. This 
so called endotype-driven treatment is one of the 4 pillars 
of precision medicine. Implementation of the principles of 
precision medicine into the management of airway diseases 
is a major challenge for the next decade [116].
Disease heterogeneity needs to be further explored 
and will lead to the discovery of new biomarkers that 
serve as a unique signature for a particular endotype. So 
far, important progresses have been made in identifying 
endotypes, of which type 2 inflammation is well ahead 
of other endotypes. Non-type 2 inflammation, the neu-
rogenic endotype and barrier dysfunction needs further 
untangling and exploration.
So far, only a limited number of biomarkers are ready 
for use in clinical practice, such as blood eosinophils or 
serum specific and total IgE. Biomarkers should be path-
way-specific, easy to measure, reproducible and afford-
able. The analysis of mediators in nasal secretions for 
endotyping is promising but requires further investiga-
tion. The biomarkers discussed in this article are mostly 
used in a research setting and represent potential bio-
markers that need to be qualified and validated. An ideal 
strategy to reach biomarker identification, qualification 
and validation is through large-scale multi-center studies 
implying cooperation and standardization of laborato-
ries and databanks all over the world. That way all efforts 
made towards precision medicine will be recognized 
more efficiently for implementation.
Besides ameliorating treatment approaches for the 
individual patients, precision medicine is thought to 
help in resolving the socio-economic burden of upper 
airway diseases [116]. It is believed that the reduction 
of the socio-economic burden due to endotype-driven 
treatment will outweigh the investments made in 
research of endotypes and development of novel treat-
ment agents. Whilst the economic aspect is a motive for 
development of endotype-driven treatments, it is the 
main challenge at the same time. Considerable invest-
ments are required to conduct research on endotypes, 
biomarkers and biologicals. Raising political awareness 
about the allergy epidemics and its socio-economics 
costs is desired and will facilitate implementation in 
clinical practice. Because of the high cost associated 
with biological treatment, these molecules will in first 
place be retained for patients with severe and uncon-
trolled disease.
Three crucial prerequisites are identified to drive the 
next step in endotype-driven therapy:
  • the demonstration of the predictive value of bio-
markers in rhinitis and CRS, guiding the clinician in 
applying precision medicine in practise
  • the recognition and better understanding of the con-
tribution of one or more immunologic pathways or 
endotypes to the disease phenotype
  • the demonstration of targeted treatment having 
superiority in clinically relevant outcomes and inferi-
ority in cost over existing treatment options.
Conclusion
This review provides an overview of the efforts made 
towards endotype-driven treatments in upper airway 
diseases. Current knowledge about type 2 inflamma-
tion is well ahead of other endotypes. Type 2 targeted 
treatments with monoclonal antibodies against IgE, IL5 
and IL4Rα have been proven to be effective in chronic 
upper airway diseases supporting the importance of this 
endotype. Neurogenic inflammation as causative mecha-
nism for nasal hyperreactivity is also well established 
and treatment with capsaicin is proven to be effective 
in IR with hyperreactivity. Barrier dysfunction and non-
type 2 inflammation still need to be investigated more 
extensively to support its importance in upper airway 
diseases. Endotype-driven treatment still needs to face 
multiple challenges before its implementation in daily 
practice.
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